Policy Advocacy in Action
Explore HLC’s policy documents that drive healthcare reform. From comment letters to federal agencies and Congressional testimony to coalition advocacy efforts, these materials demonstrate how we translate industry expertise into actionable policy recommendations that shape healthcare legislation.
Search by Keyword:
Filter by Type:
Filter by Topic:
To The Administration
HLC comments support strengthening intellectual property provisions of USMACA
To The Administration
HLC response to the Federal Trade Commission’s RFI regarding noncompete agreements
To The Administration
HLC response to the HHS/FTC/DOJ request for information regarding consolidation and the role of private equity in the healthcare sector
To Congress
HLC letter opposing Nevada’s 1332 waiver application to implement a state “public option”
To The Administration
HLC joint letter to NIST urging them to withdraw the proposed guidance on March-in rights.
To The Administration
HLC letter to The National Institute of Standards and Technology (NIST) criticizing the newly published guidance, “Draft Interagency March-In Framework.”
To Congress
HLC joint letter urging Congress to pass legislation to fix the disparity in the IRA that subjects small molecule medicines to price setting sooner than biologics
To The Administration
HLC joint letter to the Department of Commerce requesting an extension to the comment period of the request for information on an interagency march-in rights guidance framework
To Congress
HLC joint letter in support of H.R. 3799, the CHOICE Arrangement Act in advance of the House floor vote
To Congress
HLC joint letter to House W&M and Education & Workforce committees in support of affordable health coverage for employees of small businesses
To Congress
HLC letter in advance of House Education and the Workforce hearing, “Competition and Transparency: The Pathway Forward for A Stronger Health Care Market.”
To The Administration
HLC letter expressing concerns over proposals to limit intellectual property protections for COVID-19 diagnostic tools and therapeutics under the World Trade Organization’s TRIPS agreement.
Key Issues
Explore Our Policy Agenda
With a unified voice spanning the entire healthcare continuum, HLC is driving meaningful policy change to enhance the future of the U.S. healthcare system.
